Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 1, 2013, Pages

  Goyal, Vikas ^a   Chang, Anne B ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG;

ADVERSE EVENT; ARTICLE; BRONCHIECTASIS; CLINICAL OUTCOME; DISEASE DURATION; DISEASE EXACERBATION; DISEASE MARKER; DRUG EFFECT; DRUG RESPONSE; HOSPITALIZATION; HUMAN; LUNG FUNCTION; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY;

EID: 85041944477     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010327     Document Type: Article

References (27)

1. Cates C. Visual Rx. Online NNT Calculator. Cates C, 2003.
2. Cazzola M, Calzetta L, Matera MG. Beta(2) -adrenoceptor agonists: current and future direction. British Journal of Pharmacology 2011;163:4-17.
3. Chang AB, Masel JP, Boyce NC, Wheaton G, Torzillo PJ. Non-CF bronchiectasis-clinical and HRCT evaluation. Pediatric Pulmonology 2003;35(6):477-83.
4. Chang AB, Bell SC, Byrnes CA, Grimwood K, Holmes PW, King PT, et al.Bronchiectasis and chronic suppurative lung disease (CSLD) in children and adults in Australian and New Zealand: Thoracic Society of Australia and New Zealand and Australian Lung Foundation Position Statement. Medical Journal of Australia 2010;193(6):356-65.
5. Chang AB. Editorial. Bronchiectasis: so much yet to learn and to do. Paediatric Respiratory Review 2011;12:89-90.
6. Ducharme FM, Ni CM, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/14651858.CD005535.pub2]
7. Franco F, Sheikh A, Greenstone M. Short acting beta2-agonists for bronchiectasis. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD003572]
8. Gupta S, Siddiqui S, Haldar P, Raj JV, Entwisle JJ, Wardlaw AJ, et al.Qualitative analysis of high resolution computed tomography scans in severe asthma. Chest 2009;136(6):1521-8.
9. Gursel G. Does coexistence with bronchiectasis influence intensive care unit outcome in patients with chronic obstructive pulmonary disease?. Heart & Lung 2006;35(1):58-65.
10. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
11. Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD000996.pub2]
12. Keistinen T, Saynajakangas O, Tuuponen T, Kivela SL. Bronchiectasis: an orphan disease with a poorly-understood prognosis. European Respiratory Journal 1997;10(12):2784-7.
13. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Gallagher M, Holmes PW. Outcome in adult bronchiectasis. COPD 2005;2(1):27-34.
14. King P, Holdsworth S, Freezer N, Holmes P. Bronchiectasis. Internal Medicine Journal 2006;36(11):729-37.
15. Lewis MM, Mortelliti MP, Yeager H, Tsou E. Clinical bronchiectasis complicating pulmonary sarcoidosis: case series of seven patients. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases 2002;19(2):154-9.
16. Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD006826]
17. O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000;55(8):635-42.
18. Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, Wilks M, et al.Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2004;170:400-7.
19. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
20. Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respiratory Medicine 2010;104(7):981-5.
21. Santamaria F, Montella S, Pifferi M, Ragazzo V, De SS, De PN, et al.A descriptive study of non-cystic fibrosis bronchiectasis in a pediatric population from central and southern Italy. Respiration 2009;77(2):160-5.
22. Seitz AE, Olivier KN, Steiner CA, De Oca RM, Holland SM, Prevots DR. Trends and burden of bronchiectasis-associated hospitalizations: USA, 1993-2006. Chest 2010;138(4):944-9.
23. Sheikh A, Nolan D, Greenstone M. Long-acting beta-2-agonists for bronchiectasis. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD002155]
24. Singleton RJ, Morris A, Redding G, Poll J, Holck P, Martinez P, et al.Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatric Pulmonology 2000;29(3):182-7.
25. Twiss J, Stewart AW, Byrnes CA. Longitudinal pulmonary function of childhood bronchiectasis and comparison with cystic fibrosis. Thorax 2006;61:414-8.
26. Walker JK, Penn RB, Hanania NA, Dickey BF, Bond RA. New perspectives regarding beta(2) -adrenoceptor ligands in the treatment of asthma. British Journal of Pharmacology 2011;163(1):18-28.
27. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clinical Pulmonary Medicine 2005;12(4):205-9.